ANIPHealthcare · Drug Manufacturers - Specialty & GenericThe 9 Wall Street analysts covering ANI Pharmaceuticals, Inc. hold a median 12-month price target of $104 — +46.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 95 of 100 as at 27 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores ANI Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (49): The shares have been drifting down relative to others.
Size (38): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ANIP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +46.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 23 Sept 2026 | Oppenheimer | Initiates | Perform | $85 |
| 10 Aug 2026 | Canaccord Genuity | Maintains | Hold | $91 → $90 |
| 10 Aug 2026 | Canaccord Genuity | Maintains | Hold | — |
| 10 Aug 2026 | Guggenheim | Maintains | Buy | $124 → $119 |
| 10 Aug 2026 | Guggenheim | Maintains | Buy | — |
| 17 July 2026 | Canaccord Genuity | Initiates | Hold | $91 |
| 17 July 2026 | Canaccord Genuity | Initiates | Hold | — |
| 10 July 2026 | Guggenheim | Reiterates | Buy | $124 |
| 10 July 2026 | Guggenheim | Reiterates | Buy | — |
| 16 Jan 2026 | Guggenheim | Maintains | Buy | — |
| 9 Dec 2025 | Barclays | Initiates | Overweight | — |
| 10 Nov 2025 | Guggenheim | Maintains | Buy | — |
| 9 Oct 2025 | Truist Securities | Maintains | Hold | — |
| 24 Sept 2025 | JP Morgan | Maintains | Overweight | — |
| 17 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 8 Sept 2025 | Guggenheim | Maintains | Buy | — |
| 11 Aug 2025 | Truist Securities | Maintains | Hold | — |
| 8 Aug 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 July 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 12 May 2025 | Guggenheim | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ANIP appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 27 Oct 2026, ANI Pharmaceuticals, Inc. returned −23.4% against +13.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 44% of US stocks
Cheaper than 56% of US stocks
Cheaper than 34% of US stocks
Cheaper than 42% of US stocks
Higher than 75% of US stocks
Higher than 90% of US stocks
Higher than 75% of US stocks
Higher than 72% of US stocks
Higher than 72% of US stocks
Higher than 81% of US stocks
Higher than 79% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
ANI Pharmaceuticals, Inc. has a market value of $1.7B and an enterprise value of $1.8B.
Revenue in the twelve months to 30 June 2026: $978.4M. The latest quarter grew 25.9% year on year.
Net income over the same four quarters: $108.3M, a 11.1% net margin.
Diluted earnings per share, trailing twelve months: $4.64.
Free cash flow in the twelve months to 30 June 2026: $167.5M.
ANI Pharmaceuticals, Inc. spent $344K on dividends in the twelve months to 30 June 2026.
Trailing P/E: 15.7×; forward P/E: 7.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
ANI Pharmaceuticals, Inc. employs 970 people — $1.0M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own ANI Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
ANI Pharmaceuticals announced that it will release its third-quarter 2026 financial results on November 5, 2026, at 8:00 a.m. ET.
Why it matters — ANIP watchers can note the scheduled time for the company’s third-quarter results announcement.
ANI Pharmaceuticals announced the launch of Duloxetine Delayed-Release Capsules in 20, 30, and 60 mg strengths. The capsules are a generic version of the reference listed drug Cymbalta.
Why it matters — The launch adds a generic product offering to ANI Pharmaceuticals’ portfolio.
Zacks Investment Research says ANI Pharmaceuticals has a history of earnings surprises and currently has two key factors that it views as supporting the likelihood of a beat in the next quarterly report.
Why it matters — The item highlights Zacks' assessment of factors relevant to whether ANI may exceed earnings estimates in its upcoming report.
Zacks Investment Research says its Earnings ESP can help identify stocks expected to beat quarterly earnings estimates. The headline describes two medical stocks but the excerpt does not identify them.
Why it matters — The excerpt provides no specific information about ANI Pharmaceuticals, so its relevance to ANIP watchers is limited.
ANI Pharmaceuticals announced that data from its Phase 4 open-label, single-arm SYNCHRONICITY trial for fluocinolone acetonide intravitreal implant will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day at the American Academy of Ophthalmology 2026 Annual Meeting.
Why it matters — A late-breaking oral presentation of Phase 4 trial data highlights the company's clinical progress in the uveitis treatment space and increases visibility of its intravitreal implant program within the ophthalmology community.
The 9 Wall Street analysts covering ANI Pharmaceuticals, Inc. have a median 12-month price target of $104, with estimates ranging from $85 to $121. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering ANI Pharmaceuticals, Inc., 7 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ANI Pharmaceuticals, Inc. 95 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, ANI Pharmaceuticals, Inc. ranks 95 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +46.2% from the last close, and Ticker Nerd's factor model ranks ANI Pharmaceuticals, Inc. 95 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering ANI Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANIP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $85 to $121 over the next 12 months.
ANI Pharmaceuticals, Inc. returned -23.4% over the 12 months to 27 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
ANI Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and commercializes branded, generic, and specialty prescription medicines.
The most recent item we track (GlobeNewsWire, 23 Oct 2026): "ANI Pharmaceuticals to Discuss Third Quarter 2026 Financial Results on November 5, 2026 at 8:00 a.m. ET". ANI Pharmaceuticals announced that it will release its third-quarter 2026 financial results on November 5, 2026, at 8:00 a.m. ET.
ANI Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and commercializes branded, generic, and specialty prescription medicines. ANI Pharmaceuticals focuses on three main areas: Rare Disease, Generics, and Established Brands. Its portfolio includes therapies for ophthalmology, rheumatology, nephrology, neurology, and pulmonology, alongside a broad range of generic products and established branded medicines. The company also supports contract manufacturing and pharmaceutical development services, leveraging U.S.-based manufacturing capabilities and expertise in complex formulations such as injectables, softgels, oral solids, liquids, and topical products. ANI Pharmaceuticals serves patients, pharmacies, wholesalers, specialty channels, and other healthcare customers through a diversified commercial model built around prescription pharmaceuticals and niche therapeutic markets.
CEO Mr. Nikhil Lalwani · 970 employees · United States · https://www.anipharmaceuticals.com
